KDKathleen Shannon Dorcy

Kathleen Shannon Dorcy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen Shannon Dorcy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Dedicated Education Unit and a Novel Resident Nurse Transition-to-Practice Program in an Ambulatory Oncology Setting

    by Sharol Kidd, Katheryn Christiansen, Arlyce Coumar, Jill Williams, Kimberly Ito, Anna Petersen, Rae Niculescu, Seth Eisenberg, Debby Schwab, Danuta M. Wojnar, et al.


  • "I Had Already Made Up My Mind"

    by Kathleen PhD(C) Shannon-Dorcy, Denise J. PhD Drevdahl

    Background: Hematopoietic cell transplants (HCTs) are associated with high morbidity and mortality, which complicate the decision-making process for people considering HCT clinical trials. There is a lack of research examining longitudinally how patients make clinical trial participation decisions in US cancer referral centers. Objective: A qualitative study was conducted to examine how patients and their family caregivers decide to participate in HCT research at a US cancer referral center. Methods: Semistructured interviews were conducted with 25 patients enrolled in early-stage phase 2 HCT research studies and with 20 family caregivers. Interviews were conducted before HCT and approximately days 80 and 365 after HCT. Results: Most patients (92%) and their caregivers (75%) decided to participate in research well before consent conferences at the cancer referral center. Patients' reasons for deciding to participate included having "no other option," seeking a cure, and following their home oncologists' recommendations. Conclusion: Currently, US researchers are primarily guided by Federal regulations that view the decision-making process as a cognitive one. Findings confirmed cognition was a part of consent; however, most patients made the decision to participate in high-risk clinical trials long before they had been apprised of the specific information about the study and before the consent conference. Implications for Practice: The high risk of death from the disease and/or the HCT underscored the emotional component of decision making and affirmed that researchers need to acknowledge this emotional component to meet the ethical imperative of providing "informed consent."


  • Hegemony, Hermeneutics, and the Heuristic of Hope

    by Kathleen Shannon Dorcy

    Hope has become a commodity, one that society expects those who suffer to invest in and one that healthcare providers are expected to promote as an outcome. In nursing research, a single hegemonic epistemology/ontology has been implemented through an exclusive hermeneutic (interpretation of data) and has resulted in hope being designated as an external objective heuristic for those who suffer. Evidence is articulated in this article for adopting a broader method of analysis and interpretation (genealogy) that can facilitate fuller apprehension of hope in the human experience of suffering and despair.


  • Letters to the Editor

    by Denise Drevdahl, Shawn M. Kneipp, Mary K. Canales, Kathleen Shannon Dorcy

  • Nursing Implications of Mylotarg®: A Novel Antibody-Targeted Chemotherapy for CD33+Acute Myeloid Leukemia in First Relapse

    by Kathleen Shannon-Dorcy

    To review the nursing implications of gemtuzumab ozogamicin (Mylotarg(r), CMA-676, Wyeth Pharmaceuticals, Philadelphia, PA), a novel monoclonal antibody-targeted chemotherapy agent for relapsed acute myeloid leukemia (AML). Published articles, abstracts, book chapters, manufacturer information, unpublished clinical trial data, and personal experiences with gemtuzumab ozogamicin. Conventional chemotherapy for AML is associated with toxicities that often limit treatment options when AML relapses. Gemtuzumab ozogamicin is a humanized recombinant anti-CD33 monoclonal antibody linked to calicheamicin, a potent cytotoxic agent. The antibody targets the CD33 antigen found on the surface of leukemic blast cells and myeloid precursors. This targeting effect reduces the toxicity of gemtuzumab ozogamicin. The efficacy and tolerability of gemtuzumab ozogamicin have been documented in relapsed AML, particularly in patients 60 years of age or older, who often have no other treatment options. As with other monoclonal antibody therapies, an "infusion syndrome" (i.e., fever and chills) may occur but can be managed effectively when administration guidelines are used. Gemtuzumab ozogamicin is the first of a new class of targeted therapies for the treatment of relapsed AML. A number of implications for nurses exist. Nurses must be knowledgeable about gemtuzumab ozogamicin preparation and administration, patient selection and monitoring, and intervention procedures. This knowledge is necessary to accurately inform patients and their families of the possible course of treatment and potential side effects.